ClinicalTrials.gg
CompletedNCT04065932Updated Jan 6, 2021

A Study to Determine the Pharmacokinetic Profile of BMS-986165 Tablets

A Phase 1 interventional study of BMS-986165-01 and BMS-986165 Tablet in Lupus, sponsored by Bristol-Myers Squibb. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-01-06.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

A Study to Determine the Drug Level Profile of Different formulations of BMS-986165 Tablets

02

Conditions studied

  • Lupus
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Patients must be willing and able to complete all study-specific procedures and visits
  • Healthy patients, as determined by no deviation from normal in medical history, physical examination, , and clinical laboratory determinations
  • (BMI) of 18 to 32 kg/m2, inclusive, at screening
  • Normal renal function at screening

Exclusion criteria

Exclusion Criteria:

  • History or presence of chronic bacterial, viral infection, or disorder
  • Active TB requiring treatment or documented latent TB within the previous 3 years
  • Current or recent (within 3 months of study treatment administration) gastrointestinal disease that could affect absorption
  • (women of childbearing potential) must have negative serum or urine pregnancy test.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    BMS-985165-01 prototype formulation 1

    Drug: BMS-986165-01

  • Experimental
    BMS-986165 Tablet

    Drug: BMS-986165 Tablet

  • Experimental
    BMS-985165-01 prototype formulation 2

    Drug: BMS-986165-01

  • Experimental
    BMS-985165-01 prototype formulation 3

    Drug: BMS-986165-01

  • Experimental
    BMS-985165-01 prototype formulation 3 or 4

    Drug: BMS-986165-01 · Drug: Famotidine

  • Experimental
    BMS-985165-01 prototype formulation 3, 4 or 5

    Drug: BMS-986165-01 · Drug: Famotidine

Interventions

  • DrugBMS-986165-01

    Participants will receive BMS- 986165 -01 in prototype formulation

  • Participants will receive BMS-986165 in tablet form.

  • Participants will receive a previously dosed BMS-985165-01 Prototype Tablet at the same dose level following administration of famotidine

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax) for BMS-986165

    Time frame: Day 1 of treatment

  2. Area under the serum concentration-time curve from time zero to time of last quantifiable concentration- AUC(0-T) for BMS- 986165

    Time frame: Day 1 of treatment

  3. Area under the plasma concentration-time curve from time zero extrapolated to infinite time- AUC(INF) for BMS-986165

    Time frame: Day 1 of treatment

Secondary outcomes

  1. Time to maximum observed plasma concentration-(Tmax) for BMS -986165

    Time frame: Day 1 of treatment

  2. Apparent plasma elimination half-life- (T-HALF) for BMS-986165

    Time frame: Day 1 of treatment

  3. Area under the concentration-time curve from time zero to 24 hours post- (AUC 0-24) for BMS-986165

    Time frame: Day 1 of treatment

  4. Apparent clearance -(CL/F) for BMS-986165

    Time frame: Day 1 of treatment

  5. Concentration observed at 24 hours-(C24) for BMS-986165

    Time frame: Day 1 of treatment

  6. Concentration observed at 12 hours-(C12) for BMS-986165

    Time frame: Day 1 of treatment

  7. Incidence of non-serious adverse events(AE's) leading to discontinuation of study therapy.

    Time frame: Approximately 16 weeks

  8. Incidence of serious adverse events (SAE) leading to discontinuation of study therapy.

    Time frame: Approximately 16 weeks.

  9. Incidence of adverse events (AEs) leading to discontinuation of study therapy.

    Time frame: Approximately 16 weeks.

07

Study locations

1 site
  • Quotient Sciences
    Nottingham, NG11 6JS, United Kingdom
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2019 to primary completion in Dec 2019, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2019
First posted
Aug 22, 2019
StartActual
Aug 22, 2019
Primary completionActual
Dec 8, 2019
CompletionActual
Dec 10, 2019
Last update
Jan 6, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04065932
Responsible party
Sponsor
First posted
Aug 22, 2019
Start date
Aug 22, 2019
Primary completion
Dec 8, 2019
Completion
Dec 10, 2019
Last update
Jan 6, 2021

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deucravacitinib

Start the discussion